Variations on the hub-and-spoke model have blossomed in the drug development industry over the past few years — and a new antibody hub is entering the fray.
Protuoso Biosciences co-founders Willie Xiang (left) and Tim Lu
May 26, 2026 09:17 AM EDT
FinancingStartups
Exclusive: Protuoso gets $9.5M to build the next hub-and-spoke antibody developer
Kyle LaHucik
California startup Protuoso raises $9.5m for “mix-and-match” drug platform - Pharmaceutical Technology
Biohub unveils AI world model for drug discovery, enhancing protein design
Mark Zuckerberg's philanthropic venture unveils AI world model for drug discovery - The Economic Times
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
SR One’s Simeon George on how China is rewriting biotech’s venture playbook
Exclusive: Ex-Palantir AI execs raise $12 million seed round for Perceptic, a startup automating drug discovery | Fortune
Biohub builds AI atlas of proteins
bitBiome Closes Oversubscribed Seed Extension Round
Ex-Palantir team bags $12M seed to build the AI operating system pharma has been missing — TFN
Eli Lilly spending $3.8 billion to buy vaccine makers
The US biotech’s technology integrates multiple protein modalities to simultaneously target a variety of disease mechanisms.
Biohub releases open-source AI protein suite covering 6.8 billion proteins, backed by $500M in funding, to accelerate drug…
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
Lotte Biologics said Monday it signed a contract manufacturing agreement with UK biotech firm Ottimo Pharma for antibody drugs,…
Hengrui's deals with Bristol Myers and GSK aren't just licensing wins — they're the training ground for China's first truly…
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™…
